Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_872dd7cd609eb2a937dcfd303d521798 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
filingDate |
2016-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b49c0dbb025179ae6fbac12c968b2c96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_171031830578b610bc524a85a24b3a12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c04924b03c783eb88b618bcfb7b9d58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2a7c7049be5552c004dba237edacd85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_288433af1d639a157ba161e47149638d |
publicationDate |
2017-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2017021910-A1 |
titleOfInvention |
Combination treatments and uses and methods thereof |
abstract |
The present invention provides methods of treating cancer in a human in need thereof comprising administering to the human: a therapeutically effective amount of a monoclonal antibody that binds to human OX40 comprising: (a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:1; (b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:2; (c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:3; (d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:7; (e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:8; and (f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:9; and a therapeutically effective amount of a monoclonal antibody that binds to human PD- 1 comprising: (a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:54; (b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:55; (c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:56; (d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:57; (e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:58; and (f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:59. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017220988-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017220989-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017220990-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111542544-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018150326-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10766958-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3889180-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10428145-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10751414-B2 |
priorityDate |
2015-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |